Maxiphen DM is a Oral Tablet in the Human Otc Drug category. It is labeled and distributed by Mcr American Pharmaceuticals, Inc.. The primary component is Guaifenesin; Phenylephrine Hydrochloride; Dextromethorphan Hydrobromide.
Product ID | 58605-423_1a720629-daee-4f54-b8ed-6d0d69c9d1cd |
NDC | 58605-423 |
Product Type | Human Otc Drug |
Proprietary Name | Maxiphen DM |
Generic Name | Guaifenesin, Phenylephrine Hydrochloride, And Dextromethorphan Hydrobromide |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2008-03-31 |
Marketing Category | OTC MONOGRAPH FINAL / OTC MONOGRAPH FINAL |
Application Number | part341 |
Labeler Name | MCR American Pharmaceuticals, Inc. |
Substance Name | GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE |
Active Ingredient Strength | 400 mg/1; mg/1; mg/1 |
NDC Exclude Flag | E |
Listing Certified Through | 2017-12-31 |
Marketing Start Date | 2008-03-31 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | OTC MONOGRAPH FINAL |
Application Number | part341 |
Product Type | HUMAN OTC DRUG |
Billing Unit | EA |
Marketing Start Date | 2008-03-31 |
Marketing End Date | 2013-09-30 |
Inactivation Date | 2019-11-13 |
Reactivation Date | 2020-05-20 |
Marketing Category | OTC MONOGRAPH FINAL |
Application Number | part341 |
Product Type | HUMAN OTC DRUG |
Marketing Start Date | 2008-03-31 |
Marketing End Date | 2013-09-30 |
Inactivation Date | 2019-11-13 |
Reactivation Date | 2020-05-20 |
Ingredient | Strength |
---|---|
GUAIFENESIN | 400 mg/1 |
SPL SET ID: | 82f1f3c2-5aa1-4508-a585-fa109c66a120 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
58605-423 | Maxiphen DM | Guaifenesin, Phenylephrine Hydrochloride, and Dextromethorphan Hydrobromide |
63824-515 | Mucinex Fast-Max | Guaifenesin, Phenylephrine Hydrochloride, and Dextromethorphan Hydrobromide |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
MAXIPHEN DM 78330862 2953702 Dead/Cancelled |
AMBI Pharmaceuticals, Inc. 2003-11-20 |